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Roles of bone-derived hormones in type 2
diabetes and cardiovascular pathophysiology
Xuzhu Lin 1,**, Danise-Ann Onda 1, Chieh-Hsin Yang 1, Joshua R. Lewis 3,4,7, Itamar Levinger 5,6,7,
Kim Loh 1,2,*,7
ABSTRACT
Background: Emerging evidence demonstrates that bone is an endocrine organ capable of influencing multiple physiological and pathological
processes through the secretion of hormones. Recent research suggests complex crosstalk between the bone and other metabolic and car-
diovascular tissues. It was uncovered that three of these bone-derived hormonesdosteocalcin, lipocalin 2, and sclerostindare involved in the
endocrine regulations of cardiometabolic health and play vital roles in the pathophysiological process of developing cardiometabolic syndromes
such as type 2 diabetes and cardiovascular disease. Chronic low-grade inflammation is one of the hallmarks of cardiometabolic diseases and a
major contributor to disease progression. Novel evidence also implicates important roles of bone-derived hormones in the regulation of chronic
inflammation.
Scope of review: In this review, we provide a detailed overview of the physiological and pathological roles of osteocalcin, lipocalin 2, and
sclerostin in cardiometabolic health regulation and disease development, with a focus on the modulation of chronic inflammation.
Major conclusions: Evidence supports that osteocalcin has a protective role in cardiometabolic health, and an increase of lipocalin 2 contributes
to the development of cardiometabolic diseases partly via pro-inflammatory effects. The roles of sclerostin appear to be complicated: It exerts pro-
adiposity and pro-insulin resistance effects in type 2 diabetes and has an anti-calcification effect during cardiovascular disease. A better un-
derstanding of the actions of these bone-derived hormones in the pathophysiology of cardiometabolic diseases will provide crucial insights to help
further research develop new therapeutic strategies to treat these diseases.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. INTRODUCTION
Type 2 diabetes (T2D) and cardiovascular disease (CVD) and two of the
most prevailing cardiometabolic disorders in Western society and are
closely linked in terms of pathophysiology [1]. The risk of developing
CVD in individuals with T2D is two-fold higher, and CVD is the major
cause of mortality in individuals with T2D [2]. Furthermore, a cluster of
risk factors, including inflammation, obesity, dyslipidemia, and insulin
resistance appears to be unifying causal factors in both diseases [3].
Therefore, a greater understanding of pathophysiological commonal-
ities in T2D and CVD is critical for developing new precautionary
measures and treatments to simultaneously combat these diseases.
Both T2D and CVD are closely linked with bone diseases such as bone
fragility and osteoporosis [4,5]. The traditional notion that bone is an
inert organ primarily responsible for body protection and locomotion
led to assumptions that these symptoms in bone are merely outcomes
of T2D and CVD. However, in the last decade, an increasing amount of
evidence has proposed that bone as an endocrine organ that in-
fluences various organs and tissues via the secretion of multiple bone-
derived hormones [6]. These endocrinal functions are, for example,
glucose homeostasis [7], appetite control [8], fat deposition [9],
skeletal muscle adaptation [10], male fertility [11], and cognition [12].
Many comprehensive studies have shown that three of these hormo-
nesdosteocalcin (OC), lipocalin 2 (LCN2), and sclerostindare the
most closely linked to energy metabolism and cardiovascular health
[7e9,13e15]. This brand-new concept regarding bone functions
raises a possibility for dynamic crosstalk between bone and metabolic
tissues/vasculature during the development of T2D and CVD. In this
review, we will examine the evidence for the roles of OC, LCN2, and
sclerostin in metabolic and cardiovascular events. One focus is on
novel assessment of potential roles and mechanisms of each hormone
in the modulation of chronic inflammation.
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2. CHRONIC INFLAMMATION DURING THE DEVELOPMENT OF
TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
Increasing evidence has suggested that chronic inflammation is a
common underlying factor shared by T2D and CVD pathologies
[16,17]. Compared with acute inflammation, induced by infections or
autoimmune reactions, the dimensions of the chronic inflammatory
state are moderate [18]. As such, the state is often referred to as “low-
grade chronic inflammation” or “metabolic inflammation” [3]. Although
the exact underlying mechanisms have not been fully elucidated,
chronic inflammation is believed to play critical roles in various stages
of T2D and CVD development. Inflammatory reactions are often
generated by nutrition-excess-induced obesity, which is largely
attributed to a Western-style diet. In such circumstances, adipocyte
hypertrophy facilitates cell rupture [19], endoplasmic reticulum (ER)
[20], and oxidative stress [21]. These conditions lead to the enhanced
expression of inflammatory markers such as interleukin-6 (IL-6), tumor
necrosis factor-alpha (TNF-a), IL-1b, and monocyte chemoattractant 1
(MCP-1) via activation of various inflammatory pathways, such as the
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)
and c-Jun N-terminal kinase (JNK) pathways [3]. Cell apoptosis and
pro-inflammatory factor production in adipocytes subsequently attract
and activate tissue-resident macrophages. These activated macro-
phages are the main source of inflammatory mediators that leads to
exacerbations in inflammatory responses and essential for insulin
resistance in adipose tissue [22]. As a consequence, enhanced levels
of circulation based free fatty acids (FAs), glucose, and pro-
inflammatory factors induce fat accumulation and macrophage infil-
tration in other organs or tissues, including the liver [23], skeletal
muscle [24], and arterial walls [25]. These events promote systemic
inflammatory responses, which in combination with other metabolic
abnormalities such as hyperlipidemia and hyperglycemia ultimately
lead to T2D and CVD development [26].
OC, LCN2, and sclerostin have been linked with inflammatory activities
in pathological conditions such as bacterial infection and rheumatoid
arthritis [27e29], before the identification of their endocrinal functions.
More recent findings related to the regulations in cardiometabolic
health by these bone-derived hormones have attracted considerable
interest in characterizing their roles in the regulation of chronic
inflammation during T2D and CVD. Evidence shows that their effects
on inflammation are as follows: regulate inflammatory reactions in
metabolic and cardiovascular tissues, and modulate the activity and
behaviors of immune cells such as monocytes, macrophages, and
neutrophils.
2.1. Osteocalcin overview
OC is a major non-collagenous protein in bone, predominantly pro-
duced by osteoblasts [30]. Human OC is a 5.7 kilo-Dalton (KDa) peptide
containing 49 amino acids (mouse OC has 46 amino acids). During
post-translational modifications, OC can be carbonylated at its 17th,
21st, and 24th glutamine (Glu) residues into carboxylated OC (cOC)
[31]. In bone, there remains a small proportion of OC with one or more
uncarboxylated Glu residues (termed undercarboxylated OC [ucOC]),
and in the general circulation where the percentage of ucOC is much
higher (40%e60%) with physiological serum levels normally below
30 ng/mL (in mice < 50 ng/mL) [32,33]. Although the paracrinal
functions of OC in bone have not been fully elucidated, it has been
shown that OC suppresses bone formation and mineralization, without
impairing bone resorption [34,35]. Many studies have demonstrated
that OC functions as a bone-derived hormone involved in multiple
biological processes, including energy metabolism [7], cardiovascular
health [36], male fertility [11], cognition [12], and stress response [37].
List of abbreviations
8-iso-PGF2a 8-iso-prostaglandin F2a
AP-1 activator protein 1
ApoE apolipoprotein E
ATF6 activating transcription factor 6
BAT brown adipose tissue
cOC carboxylated OC
CVD cardiovascular disease
CXCR2 the chemokine C-X-C motif receptor 2
eNOS endothelial nitric oxide synthase
ER endoplasmic reticulum
ERK1/2 extracellular signal-regulated protein kinase 1/2
FAs fatty acids
GLP-1 glucagon-like peptide-1
Glu glutamine
GPRC6A the G protein-coupled receptor
family C group 6 member A
GPx-1 glutathione peroxidase 1
GSH glutathione
GSSG glutathione disulfide
HAECs human aortic endothelial cells
HASMCs human aortic smooth muscle cells
HFD high-fat diet
HPASMCs human pulmonary artery smooth muscle cells
hs-CRP high sensitivity C-reactive protein
HUVECs human umbilical vein endothelial cells
IKK the IkB kinase
IL-6 interleukin-6
IRE-1 inositol-requiring kinase 1
JNK c-Jun N-terminal kinase
KDa kilo-Dalton
LCN2 lipocalin 2
LDL low-density lipoprotein
LOX-1 lectin-type oxidized LDL receptor 1
LPS lipopolysaccharides
LRPs LDL receptor related proteins
MC4R melanocortin-4 receptor
MCP-1 monocyte chemoattractant 1
MDA malondialdehyde
NASH non-alcoholic steatohepatitis
NF-kB the nuclear factor kappa-light-chain-enhancer
of activated B cells
NGAL neutrophil gelatinase-associated lipocalin
NLRP3 nucleotide-binding domain-like receptor protein 3
NO nitric oxide
Nrf2 nuclear factor erythroid 2-related factor 2
OC osteocalcin
PERK the double-stranded RNA-activated
protein kinase-like ER kinase
SOD superoxide dismutase
SRA-1 scavenger receptor A-1
T2D type 2 diabetes
TNF-a tumor necrosis factor-alpha
ucOC undercarboxylated OC
WAT white adipose tissue
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These physiological functions have been recognized to be primarily
regulated by ucOC [31], although some studies have suggested that
cOC may also be biologically active [38,39].
2.2. Beneficial roles of osteocalcin in energy metabolism and
metabolic disorders
A considerable amount of evidence in mice supports that ucOC im-
proves glucose homeostasis and energy balance (Figure 1) [31,32]. In
2007, Lee et al. showed that an OC deficiency in mice led to adipocyte
hypertrophy, insulin resistance, glucose intolerance, and high circu-
latory triglyceride levels [7]. By contrast, in the “gain-of-function”
mouse model, which had higher ucOC levels, mice exhibited hypo-
glycemic phenotypes [7]. Moreover, mice deficient in the G protein-
coupled receptor family C group 6 member A (GPRC6A), the putative
receptor for ucOC, exhibited metabolic syndrome similar to that re-
ported for OC/- mice [40]. This milestone paper not only proved that
OC plays an important role in energy and glucose homeostasis but
alsodfor the first timedshowed that a hormone produced by bone
regulates physiological processes not directly linked with bone
maintenance. While two recent studies showed no metabolic abnor-
malities in mice with osteocalcin deficiency (Diegel et.al 2020 Plos
Genetics & Moriishi et.al 2020 Plos Genetics), these discrepancies
could be attributed to differences in genetic modification methods,
mouse genetic backgrounds or housing environments [164,165].
Nonetheless, strong evidence suggested that ucOC exerted its meta-
bolic effects by targeting multiple tissues essential for glucose and lipid
metabolism. In the pancreas, ucOC has been reported to directly in-
crease cell proliferation, Ins expression, and insulin secretion in b-cells
Figure 1: Roles of osteocalcin in cardiometabolic regulation and disease. Figure 1 incorporates findings from animal models and humans. The majority of OC, including its
active form ucOC, is produced by osteoblasts [30]. During CVD, cardiovascular tissues also express OC to a much lesser extent, probably as an osteogenic marker [59,60]. The
literature suggests that ucOC benefits energy metabolism and cardiovascular health in physiological states. First, ucOC promotes b-cell proliferation and insulin production in
pancreas [42,46]. ucOC also indirectly favors insulin production via enhancing GLP-1 secretion from intestine [43]. Furthermore, in insulin target tissues such as WAT, liver, and
muscle, ucOC suppresses adipocyte size [46], increases glucose and FA uptake [10,44], enhances insulin sensitivity [45], and promotes nutrient utilization and mitochondrial
capacity [10]. ucOC also reduces lipid synthesis in liver and glycogen production in muscle [10,49]. ucOC also enhances cell proliferation in HAECs and HASMCs [61]. During T2D
and CVD, ucOC levels are decreased [50e52]. In insulin target tissues, the administration of ucOC suppresses excessive fat deposition, ameliorates insulin resistance, and restores
impaired mitochondrial capacity [47,86]. The administration of ucOC has also been demonstrated to exert rescuing effects on vasculature during CVD. ucOC has been demonstrated
to reduce atherosclerotic plaque formation and arterial stiffness [14,58]. In various types of vascular cells, ucOC enhances cell survival and expression of eNOS and NO [14,62,63].
Numerous studies suggest an anti-inflammatory role of ucOC in cardiometabolic syndromes. In WAT and liver, ucOC reduces macrophage infiltration [78], inflammatory factor
expression [39], and the activation/translocation of pro-inflammatory nuclear factors [76]. ucOC also decreases ER stress in insulin target tissues and vascular cells [14,48].
Moreover, ucOC attenuates inflammation in liver by mitigating oxidative stress [75].Short-head arrows: secretion. Long-head arrows: suggested OC effects. Green texts: direct
beneficial effects on cardiometabolic tissues in T2D or CVD conditions. Blue texts: anti-inflammatory effects in T2D or CVD conditions. OC e osteocalcin; ucOC e under-
carboxylated osteocalcin; T2D e type 2 diabetes; CVD e cardiovascular disease; GLP-1e glucagon-like peptide-1; WAT e white adipose tissue; FA e fatty acid; HAECs e human
aortic endothelial cells; HASMCse human aortic smooth muscle cells; eNOS e endothelial nitric oxide synthase; NO e nitric oxide; ER e endoplasmic reticulum.
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[41,42]. ucOC may also enhance insulin secretion in the pancreas by
increasing the production of glucagon-like peptide-1 (GLP-1) from the
intestines [43]. In major insulin target tissues, such as white adipose
tissue (WAT), liver, and skeletal muscle, ucOC directly enhances
glucose and FA uptake [10,39,44], insulin sensitivity [45e47], nutrient
utilization [10,39], and mitochondrial capacity [10,41,48] and reduces
glycogen and lipid synthesis [10,49].
Notably, literature has reported that the circulating levels of ucOC are
reduced in both humans and mice in the presence of metabolic syn-
dromes such as insulin resistance and T2D [50e52] and that these
disorders can be ameliorated by administering ucOC (Figure 1)
[7,38,41,46e48,52]. ucOC administration to obese diabetic mice has
been demonstrated to improve systemic glucose tolerance and insulin
sensitivity, concomitant with reductions in hyperlipidemia and whole-
body adiposity [38,41,48]. Consistently, the overexpression of ucOC
protected mice from obesity and glucose intolerance induced by gold
thioglucose injection [7]. In insulin-resistant muscle, liver, and WAT,
the treatment of ucOC restores impaired response to insulin stimula-
tion, perturbed energy metabolism, and compromised mitochondrial
capacity [46e48,52].
The human evidence related to a possible causal relationship between
OC-GPRC6A axis and energy metabolism appears contradictory to the
findings of mice studies. Genetic evidence suggests that a loss-of-
function mutation in GPRC6A was accompanied by glucose intoler-
ance in two patients [11]. Furthermore, a polymorphism rs1800247 in
the OC gene and a rs2274911 polymorphism in the GPRC6A gene have
been be associated with insulin resistance [53,54]. However, two
recent studies have suggested limited effects of ucOC in humans by
reporting that ucOC reduction, via a 3-year Vitamin K supplementation,
had no impact on body composition in older men and women [55,56].
Thus, it remains too early to conclude whether the metabolic effects of
ucOC reported in mice models also exist in humans. To clarify the
therapeutic potential of ucOC, further research is necessary to reveal
metabolic regulations via ucOC in human tissues and cells.
2.3. Beneficial role of osteocalcin in protecting cardiovascular
health
Unlike ucOC metabolic functions, OC mechanistic insights in cardio-
vascular health are fewer and equivocal. Several animal studies have
suggested that ucOC may protect vasculature under T2D conditions
(Figure 1) [14,57,58]. For instance, ucOC administration improved
diastolic blood pressure, endothelium-dependent relaxation, and aortic
atherosclerotic plaque formation in high-fat diet (HFD)-fed apolipo-
protein E (ApoE)/ mice [14]. In diabetic rats, the enhancement of
circulatory ucOC, either by ucOC or warfarin administration, improved
arterial stiffness, vascularization, capillary density, and neo-
vascularization and decreased myocardial fibrosis [57,58]. However,
whether these improvements are from ucOC acting directly on vascular
cells or are as a consequence of improved metabolic outcomes re-
mains unknown.
Evidence from in vitro studies has demonstrated direct protective ef-
fects of ucOC on the vasculature [14,59e63]. The treatment of ucOC at
physiological levels was reported to enhance cell proliferation in hu-
man aortic endothelial cells (HAECs) and human aortic smooth muscle
cells (HASMCs) [61]. In pathological conditions, ucOC treatment also
exerted protective effects on multiple cell types in human vessel walls
(i.e., aortic endothelial, umbilical vein endothelial, and smooth muscle
cells). These protective effects were generated by increasing the
activation and expression of endothelial nitric oxide synthase (eNOS)
and nitric oxide (NO) [14,62,63] and reducing cell apoptosis induced by
FAs [62]. ucOC treatment (10 ng/mL) also attenuated atherogenic diet-
induced impairment of endothelium-dependent vasorelaxation in the
rabbit aorta [36]. Nevertheless, compared with circulating ucOC
secreted from bone, locally expressed OC in vascular smooth muscle
cells [59,60], endothelial progenitor cells [64], platelets [65], and
monocytes [66] have been associated with arterial calcificationda
hallmark of advanced atherosclerosis. However, because OC has been
one of the best molecular markers for osteogenic transcriptional
programs [67], whether non-bone-derived OC is an active player
potentiating CVD development or merely a osteogenic marker requires
further investigation.
These findings suggest direct protective effects of OC on vasculature
during CVD, athough the overall effects of ucOC on cardiovascular
health may be mainly from its metabolic effects.
2.4. Anti-inflammatory role of osteocalcin in cardiometabolic
disorders
As described, ucOC probably has therapeutic effects against T2D and
CVD [7,14]. Therefore, a possibility is that ucOC exerts these beneficial
effects, at least partially, by suppressing chronic inflammation. Indeed,
accumulating correlational evidence has shown that OC perturbations
in T2D and CVD are associated with inflammation, for example, high
sensitivity C-reactive protein (hs-CRP), a marker of systemic inflam-
mation, was reported to be inversely associated with circulating total
OC and ucOC levels in patients with T2D [68e70]. Other inflammatory
markers such as TNF-a, IL-6, and ferritin were also negatively asso-
ciated with serum ucOC levels in T2D or pre-diabetic patients [71,72].
In addition, ucOC was negatively correlated with several chronic
inflammation parameters, including total leukocyte, neutrophil, and
monocyte counts in T2D patients [73].
The anti-inflammatory roles of ucOC have been investigated in several
mechanistic studies, using both in vivo and in vitro models (Figure 1)
[74,75]. The administration of ucOC to ApoE/ mice challenged with
a HFD reduced circulatory levels of several inflammatory cytokines,
including TNF-a, IL-1a, and IL-12 [14]. In WAT, ucOC administration
reportedly decreased macrophage infiltration in mice with hypotha-
lamic obesity [76]; it also reduced the expression of macrophage
markers and inflammatory genes such as Cd68, F4/80, Mcp1, Tnf,
Nlrp3, Ciita, and Cd74, in lean [77] and HFD-fed mice [74]. In the liver,
ucOC suppressed diet-induced JNK activation and inflammatory gene
expression [74,75]. Notably, these anti-inflammatory ucOC effects can
probably be passed to offspring via epigenetic inheritance, because
male pups from ucOC-administered female mice were protected from
high energy diet-induced pro-inflammatory marker expression, and
macrophage infiltration in both WAT and liver [78]. In in vitro models,
ucOC treatment (20 ng/mL) in 3T3-L1 adipocytes attenuated TNF-a-
induced enhancement of several inflammatory marker genes,
including Tnf, Ccl2, Nfkb1, and Rela, and the nuclear content of the NF-
kB p65 subunit [76]. In primary rat adipocytes, ucOC at 20 ng/mL also
suppressed TNF-a production [39].
In contrast to the aforementioned evidence, suggesting an anti-
inflammatory role for ucOC, other evidence has indicated that the ef-
fects of ucOC on inflammatory gene regulation may be multifaceted.
For example, ucOC does not influence IL-6, IL-8, or MCP-1 expression
levels in either acute or chronic inflammation in in vitro human vascular
cells [79]. Additionally, ucOC treatment enhanced IL-6 expression in
adipocytes [39] and myotubes [10].
Collectively, these data suggest that ucOC ameliorates inflammation in
mice with metabolic disorders, especially in WAT and the liver. How-
ever, because ucOC has profound metabolic effects, whether these
proposed anti-inflammatory effects are merely outcomes from the
reduction of hyperglycemia and hyperlipidemia remains unclear. Thus,
Review
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further research is necessary to show that ucOC directly regulates
inflammatory factors and signaling pathways, under pathological and
metabolically inflammatory conditions. One question that must be
addressed is whether ucOC exerts its effects on myeloid lineage cells,
because macrophages play key roles in insulin resistance and
atherosclerosis. Although there is no direct evidence, the likelihood of a
direct effect of ucOC on myeloid cells is high because the expression of
GPRC6A has been found in mouse and human monocytes [80] and in
peritoneal [81] and RAW264.7 macrophages [82].
2.5. Osteocalcin-induced suppression of endoplasmic reticulum
stress and oxidative stress
A potential mechanism for how ucOC directly ameliorates chronic
inflammation in different cells and tissues is the suppression of ER
stress (Figure 1). As aforementioned, ER stress appears to provoke
inflammation in T2D and CVD. Under these conditions, the build-up of
ER stress via nutrient overload [83], unfolded protein accumulation [83],
and high lipid levels [84] triggers signaling pathways modulated by three
ER based sensing proteins: double-stranded RNA-activated protein
kinase-like ER kinase (PERK), inositol-requiring kinase 1 (IRE-1), and
activating transcription factor 6 (ATF6) [85]. Notably, the activation of ER
stress pathways leads to JNK and the IkB kinase (IKK) phosphorylation,
which translocates nuclear factor activator protein 1 (AP-1) and NF-kB,
thereby promoting inflammatory factor expression [85].
In mice, ucOC administration has been demonstrated to inhibit the
HFD-induced enhancement of PERK and IRE-1a phosphorylation and
ATF6b expression in WAT, liver, skeletal muscle, and aorta cells
[47,48,86]. In addition, in vitro ucOC treatment (5 ng/mL) reduced
PERK and IRE-1a phosphorylation, and ATF6b expression induced by
tunicamycin, in 3T3eL1 adipocytes, Fao liver cells, L6 muscle cells,
vascular endothelial cells, and vascular smooth muscle cells
[47,48,86]. Notably, NF-kB activation was involved in the suppression
effects of ucOC on ER stress in in vitro models [48]. However, whether
ucOC administration suppressed the expression of pro-inflammatory
factors was not reported. Moreover, because NF-kB activation is
widely accepted as a central mediator in nutrient excess-induced
inflammation [87], the proposed mechanisms based on in vitro
models may not explain the ucOC effects on ER stress in vivo.
Therefore, whether and how ucOC suppresses chronic inflammation
via ER stress relief requires further exploration.
ucOC has been suggested to suppress chronic inflammation via
oxidative stress mitigation (Figure 1). Oxidative stress is implicated in
several molecular inflammatory events during T2D and CVD, namely,
low-density lipoprotein (LDL) oxidation [88] and the activation of
nucleotide-binding domain-like receptor protein 3 (NLRP3) inflamma-
somes [89]. In the liver of HFD-fed mice, ucOC administration reduced
oxidative stress biomarker expression, including malondialdehyde
(MDA), 8-iso-prostaglandin F2a (8-iso-PGF2a), and glutathione di-
sulfide (GSSG)/glutathione (GSH) ratios [75]. This hepatic oxidative
stress relief was probably due to the up-regulation of other antioxidant
enzymes, including catalase, superoxide dismutase (SOD), and
glutathione peroxidase 1 (GPx-1), via activation of the nuclear factor,
nuclear factor erythroid 2-related factor 2 (Nrf2) [75]. In another study,
ucOC suppressed oxidative stress induced by high glucose levels in
MC3T3-E1 cells [90]. However, as the evidence is scarce and sug-
gestive, further investigations are required to discern the possible
effects of ucOC on oxidative stress.
2.6. Lipocalin 2 overview
LCN2, also termed 24p3 or neutrophil gelatinase-associated lipocalin
(NGAL), is a 25 kD glycoprotein that in physiological states (normally
<100 ng/mL in human serum [91], <200 ng/mL in mouse serum [8])
has been linked with numerous functions such as neutrophil function
[92], mechanoresponsive gene regulating bone homeostasis in
response to exercise/inactivity [93], and skeletal muscle regeneration
[94]. It has been suggested that in physiological state lipocalin 2 is
polyaminated [95] and expressed predominantly from bone cell oste-
oblasts [8]. In bone, LCN2 is regulated by physical activity/inactivity
[93] and negatively modulates bone development and turnover, as
LCN2 overexpression in mouse bone results in thinner cortical bone
and reduces osteoblast differentiation [96]. Recently, bone-derived
LCN2 was shown to have endocrinal functions in appetite control
and insulin secretion in mice [8]. However, in pathological states, LCN2
expression can probably be induced in a wide range of cells and tis-
sues, including adipose tissue [97,98], kidney [99], liver [100], and
vasculature [101]. As such, increased circulating LCN2 is often used as
a pathological biomarker such as acute kidney injury [102]. In path-
ological conditions, it was shown that two other forms of LCN2dR81E
and deamidated LCN2dwere expressed at least in WAT [95,103].
Thus, pathological forms of LCN2 probably display diverse ligand-
binding and post-translation modifications, depending on the
different tissue/cell sources, further complicating their causal roles in
acute and chronic diseases.
2.7. Endocrine regulations of energy metabolism by lipocalin 2
Recent evidence has suggested that LCN2 plays a vital role in energy
metabolism and is closely related to diabetes [8,104,105]. Human
studies have demonstrated that higher circulating LCN2 levels are
associated with obesity, insulin resistance, and dyslipidemia in T2D
patients, thereby proposing LCN2 as a serum marker for metabolic
disorders [106,107]. Some evidence from animal models has also
linked adverse metabolic effects to LCN2 [108e110]. Law et al.
showed that LCN2 deficiency protected mice from aging and obesity-
induced insulin resistance [110]. In another study, mice with systemic
LCN2 overexpression, exhibited enhanced fat mass and adipocyte size,
accompanied by increased food intake, glucose intolerance, and in-
sulin resistance [109]. Additionally, Jun et al. reported that LCN2/
mice exhibited modestly improved glucose tolerance compared with
that of their WT littermates [108].
Nevertheless, despite the clinical associations and the above-
mentioned animal studies, numerous mechanistic insights from animal
models have demonstrated that LCN2 is important for multiple
metabolic processes in various tissues, including appetite control,
insulin production, and thermogenesis (Figure 2) [8,104,105,111e
113]. The loss of LCN2 in osteoblasts [8] or a global LCN2 defi-
ciency [105] in mice was reported to lead to obesity and insulin
resistance because of enhanced food intake. In line with this finding,
LCN2 administration in mice resulted in reduced food intake by acting
on the melanocortin-4 receptor (MC4R) receptor in the hypothalamus,
suggesting an anorexigenic effect for LCN2 [8]. Furthermore, bone-
derived LCN2 was shown to exert beneficial effects on the pancreas,
because the specific loss of LCN2 from osteoblasts led to impaired
insulin secretion and b-cell proliferation [8]. Other studies have indi-
cated that LCN2 may regulate brown adipose tissue (BAT) to enhance
thermogenesis and energy expenditure, because LCN2 loss in mice
resulted in compromised adaptive thermogenesis, and potentiated
diet-induced obesity, dyslipidemia, fatty liver disease, and insulin
resistance [111e113]. Consistently, LCN2 overexpression in adipose
tissue protected against an aging-induced decline in thermogenic
functions and promoted glucose tolerance and lipid homeostasis [104].
The discordant findings from animal models with genetic manipula-
tions are probably due to the genetic and environmental factors
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selected for these models, leading to differences in LCN2 post-
translational modifications including dimeriation and polyamidation
[114], and differences in LCN2 production sites. In addition, complex
technical issues such as targeting strategies for knockout mice and
housing environments could also be responsible for these discrep-
ancies [115].
In vitro evidence also suggests divergent direct metabolic effects of
recombinant LCN2 in different cell types. In primary pancreatic islets,
the treatment of physiological levels LCN2 (10e100 ng/mL) enhanced
glucose-induced insulin secretion [8]. In 3T3-L1 adipocytes, LCN2
treatment (250 ng/mL) increased fatty acid b-oxidation in mature cells
[116]. Nevertheless, LCN2 treatment promoted insulin resistance in
H4IIe hepatocytes (250 ng/mL) [117] and human adipose tissue
(100 ng/mL) [118], and LCN2 knockdown in 3T3-L1 adipocytes
increased insulin sensitivity [117]. However, in these studies, either the
physiological or pathological levels of LCN2 were used for the treat-
ment; thus, an assessment of whether different levels of LCN2 yield
different metabolic outcomes is necessary.
Collectively, although studies have suggested several endocrine
functions of LCN2 in energy metabolism, there is little consensus on
the subject. To resolve these discrepant findings, further research
must identify the modification status and metabolic functions of bone-
derived LCN2 versus LCN2 secreted from other tissues and compare
their roles in physiological and T2D conditions.
2.8. Detrimental role of lipocalin 2 in the development of
cardiovascular disease
Observational studies have demonstrated that increased systemic
LCN2 levels are associated with the severity of coronary artery disease
[119] and increased risk of future CVD events [120e122]. Unlike LCN2
Figure 2: Roles of lipocalin 2 in cardiometabolic regulation and disease. Figure 2 incorporates findings from animal models and humans. LCN2 is probably mainly produced
in osteoblasts in physiological states [8] and plays an important role in energy homeostasis. In brain, LCN2 controls appetite via its effect on hypothalamus in an MC4R-dependent
manner [8]. Furthermore, LCN2 promotes b-cell proliferation and insulin production in pancreas [8]. In addition, LCN2 favors adaptive thermogenesis and energy metabolism in
brown adipose tissue [104,111]. In vasculature, LCN2 favors the growth and survival of SMCs [124e126]. In the conditions of T2D and CVD, the circulating levels of LCN2 are
considerably increased due to inductive expressions in WAT [124e126], liver [100], and cardiovascular tissues [101], as well as due to enhanced deamidation [95]. Pathological
levels of LCN2 potentiates insulin resistance in adipose tissue and liver in T2D [116,117]. During CVD, increased levels of LCN2 contributes to aortic aneurysm [15], endothelial
dysfunction [95,123], cell autophagy inhibition [101], and mitochondrial damage in heart tissue [101]. The detrimental roles of LCN2 in cardiometabolic syndromes are closely
linked with its pro-inflammatory effects. LCN2 drives immune cell infiltration and NLRP3 inflammasome-induced inflammatory factor expression [100,101]; furthermore, it causes
inflammation-related injury in liver and ER stress in smooth muscle cells [100,124]. LCN2 also directly activates immune cells during cardiometabolic syndromes. In monocytes/
macrophages, it enhances cell migration, M1 polarization, and foam cell formation [129]. In neutrophils, LCN2 increases CXCR2 expression and the production of pro-inflammatory
factors [101]. Short-head arrows: secretion; differentiation. Long-head arrows: suggested LCN2 effects. Orange texts: direct detrimental effects on cardiometabolic tissues in T2D
or CVD conditions. Red texts: pro-inflammatory effects in T2D or CVD conditions. LCN2 e lipocalin 2; MC4R e melanocortin-4 receptor; SMCs e smooth muscle cells; T2D e type
2 diabetes; CVD e cardiovascular disease; WAT e white adipose tissue; NLRP3 e nucleotide-binding domain-like receptor protein 3; CXCR2 e the chemokine The meaning was
unclear. Thus, changes were made. Please ensure the changes preserve the intended meaning.-X-C motif receptor 2.
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roles in metabolic disorders, mechanistic studies conducted on LCN2-
KO mice have demonstrated possible causeeeffect relationships be-
tween LCN2 and the development of atherosclerotic disease (Figure 2).
In Tarín et al., LCN2/ mice or mice treated with LCN2 antibodies
showed a decreased incidence of abdominal aortic aneurysm and
reduced aortic expansion compared with that of WT mice or mice
treated with IgG (control), respectively [15]. In two other studies, LCN2-
deficient mice were protected from dietary challenge-induced endo-
thelial dysfunction, reflected by enhanced blood pressure, impaired
endothelium-dependent relaxation, and augmented endothelium-
dependent contractions [95,123]. Notably, LCN2 activity seemed to
be influenced by its polyamidation status, which contributes to LCN2
removal from general circulation [95]. The administration of the dea-
midated recombinant LCN2 in mice has led to severe endothelial
dysfunction, compared with WT recombinant LCN2 administration
[95].
In contrast to these in vivo findings, some in vitro evidence suggests
that physiological levels of LCN2 may have beneficial effects on
smooth muscle cells. In a series of studies by Wang and colleagues,
the stimulation of 3e30 ng/mL LCN2 in human pulmonary artery
smooth muscle cells (HPASMCs) promoted pro-proliferative and anti-
apoptotic effects, despite increased ER stress [124e126]. However,
it remains possible that LCN2, at much higher pathological levels,
leads to cell damage and cell death in the vasculature, but evidence
has not been provided.
Collectively, LCN2 enhancement in cardiovascular disorders, especially
in the deamidated form, seems to accelerate CVD progression. What
remains unclear is whether the changes in LCN2 expression are from
physiological sources such as bone, and where the deamidated form of
LCN2 is majorly produced. Therefore, during CVD, the modification
statuses and roles of the LCN2, which originated from different pro-
duction sites, must be established and clarified.
2.9. Pro-inflammatory role of lipocalin 2 in cardiometabolic
disorders
Of all known factors produced by bone, LCN2 is the most closely
implicated in inflammation. Notably, LCN2 was initially identified and
purified from neutrophil granules [127]. In LCN2 functional studies on
innate immune responses, it was suggested to play important roles in
bacterial capture [128], and sterile inflammation [27]. However,
several later studies, with both in vivo and in vitro findings, showed
that LCN2 provoked inflammatory responses in myeloid cells and
cardiovascular tissues during CVD (Figure 2) [15,100,101].
In a mouse study by Tarín et al., LCN2 deficiency or the administration
of LCN2 antibodies decreased neutrophil infiltration into the aortic wall
during abdominal aortic aneurysm [15]. Other in vivo data showed that
in low-density lipoprotein receptor-deficient (ldlr /) mice fed an HFD
and high-cholesterol diet, LCN2 was co-localized with infiltrated
macrophages in atherosclerotic plaques [100]. Moreover, in mouse
heart tissue, an LCN2 deficiency led to reductions in pressure
overload-induced NLRP3 inflammasome activation, accompanied by
reduced autophagy and mitochondrial damage, which were reversed
by WT LCN2 restoration via recombinant adenovirus expression [101].
In vitro findings also suggests a pro-inflammatory role of pathological
levels of LCN2. In bone marrow-derived macrophages, LCN2 stimu-
lation (500 ng/mL) up-regulated the M1 macrophage gene markers,
Tnf, Nos2, Il6, and Ccl5 [129]. Furthermore, LCN2 treatment (500 ng/
mL) facilitated the formation of macrophage foam cells, via increased
lectin-type oxidized LDL receptor 1 (LOX-1) and scavenger receptor A-
1 (SRA-1) expression [129]. In monocytic J774A.1 cells, enhanced
migration induced by LCN2 treatment (500 ng/mL) was also observed
[129]. In another in vitro study, LCN2 treatment (200e1000 ng/mL) in
human umbilical vein endothelial cells (HUVECs) and HASMCs signif-
icantly enhanced secretion of the pro-inflammatory cytokines, IL-8, IL-
6, and MCP-1 in a dose-dependent manner [130]. In primary cardiac
fibroblasts, LCN2 at 1000 ng/mL enhanced priming and activation of
NLRP3-inflammasomes, as evidenced by the increased expression of
IL-1b and IL-18, as well as caspase-1 activation [101].
In addition to its inflammatory role in CVD, LCN2 regulates chronic
inflammation in other metabolic disorders (Figure 2). In a recent study
using mice with diet-induced non-alcoholic steatohepatitis (NASH), the
genetic depletion of LCN2 substantially reduced hepatic injury, pro-
inflammatory gene expression, and neutrophil and macrophage infil-
tration [100]. In the same study, LCN2 administration in mice with
NASH exacerbated hepatic inflammation and immune cell accumula-
tion in a neutrophil-dependent manner [100]. In another study by Law
et al., LCN2 deficiency in mice led to reduced fat mass and less
macrophage infiltration in WAT tissue, along with decreased expres-
sion of inflammatory gene markers, including Tnf, F4/80, Mcp-1, and
Cd14 [110]. In compatible with the in vivo findings, ex vivo LCN2
treatment (100e10000 ng/mL) in primary neutrophils enhanced
expression of the chemokine C-X-C motif receptor 2 (CXCR2), leading
to the activation of extracellular signal-regulated protein kinase 1/2
(ERK1/2), production of pro-inflammatory cytokines, and enhanced cell
migration [100].
2.10. Sclerostin overview
Sclerostin is a secreted glycoprotein that contains 190 amino acids.
Most circulatory sclerostin is produced by osteocytes [131]; however,
several other tissue types, such as liver, kidney, and the vascular wall,
may also produce glycoprotein [132]. Sclerostin is a strong suppressor
of bone mass accrual, because of its antagonizing effects on the Wnt/
b-catenin signaling pathway (canonical Wnt pathway) via binding to
LDL receptor-related proteins (LRPs) [133]. As such, targeting the
paracrine actions of sclerostin in bone is an effective approach for anti-
resorptive therapies, such as the administration of the sclerostin
monoclonal antibodies romosozumab and blosozumab [134]. Outside
the bone, sclerostin is abundantly expressed in the general circulation,
with normal physiological levels below 1 ng/mL [135]. Because Wnt/b-
catenin signaling pathway is a key regulator of cellular functions,
including proliferation, differentiation, and migration in various tissues
[136], an endocrine role of bone-derived sclerostin has also been
demonstrated [9,137].
2.11. Role of sclerostin in promoting adiposity and insulin
resistance
It was proposed that the endocrine functions of sclerostin involve
negative regulations of glucose and fatty acid metabolism via up-
regulating whole-body adiposity, because activators of the canonical
Wnt pathway have been implicated as potent inhibitors for adipo-
genesis [138,139]. Indeed, recent clinical observations have sug-
gested that higher sclerostin levels are associated with higher fat
mass, as well as lower peripheral insulin sensitivity [140,141].
Consistent with these clinical reports, a recent mechanistic study
demonstrated that sclerostin deficiency in mice resulted in reduced
adipose tissue accumulation, improved whole-body and muscle insulin
sensitivity and decreased hepatic gluconeogenesis [9]. In another
study, the loss of the functional receptor LRP4 in fat tissue led to
smaller adipocyte size and increased whole-body insulin response
[137]. Additionally, in several mice models with sclerostin over-
production, enhanced fat mass and compromised insulin sensitivity
were observed [9,137,142]. However, another recent study reported
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that sclerostin overexpression may have beneficial effects on energy
metabolism by facilitating beige adipogenesis [143], indicating that the
physiological roles of sclerostin may be more complex than originally
perceived.
In pathological states such as T2D, there are much higher serum
sclerostin levels compared with those of healthy controls [144,145],
indicating that an increase in sclerostin may contribute to disease
development. Consistently, either sclerostin deficiency or the admin-
istration of sclerostin antibody protected mice from HFD-induced
obesity, hyperglycemia, hyperlipidemia, insulin resistance, and fat
deposition in the liver [9]. In in vitro adipocytes, pathological levels of
sclerostin enhanced cell differentiation, increased fatty acid synthesis,
and reduced fatty acid oxidation in either 3T3-L1 (5e20 ng/mL) [146]
or primary cells (100 ng/mL) [9,137], contributing to adipocyte
hypertrophy.
Collectively, despite the majority of studies promoting adverse meta-
bolic effects of sclerostin in physiological and pathological states
(Figure 3), its detailed regulatory mechanisms in adipose tissue re-
quires further investigation.
2.12. Protective role of sclerostin in vascular calcification
As WNT-b-catenin plays an important role in CVD onset and devel-
opment [147], potential crosstalk between bone and vasculature via
sclerostin has attracted increased attention. Although cross-sectional
studies have reported that enhanced sclerostin levels are associated
with poor CVD outcomes [148,149], romosozumab (a humanized
monoclonal antibody for sclerostin) clinical trials for osteoporosis
treatment have suggested an increased CVD risk when compared with
that of alendronate [150,151], indicating that sclerostin may benefit
cardiovascular health. Recently, sclerostin was proposed to have a
preventative action on vascular calcification in complicated athero-
sclerotic plaques, similar to its role in inhibiting mineralization pro-
cesses in the bone (Figure 3) [152,153]. In ApoE/- mice treated with
angiotensin II, sclerostin overexpression induced inhibitory effects on
the progression of aortic aneurysm and atherosclerosis [13]. Notably,
sclerostin expression was considerably increased in different cell types
within atherosclerotic plaques [154,155], and it appears to be a
counter-regulatory mechanism suppressing vascular calcification
development. However, the hormonal action of bone-derived sclerostin
Figure 3: Roles of sclerostin in cardiometabolic regulation and disease. Figure incorporates findings from animal models and humans. Sclerostin is predominantly secreted
from osteocytes [131], although a smaller amount can also be produced in other tissues, such as vasculature during CVD as a possible compensatory mechanism to counter
vascular calcification [132]. In physiological states, sclerostin downregulates energy metabolism via enhancing adiposity and reducing insulin sensitivity [9,137]. It also enhances
gluconeogenesis in liver [9]. However, it could also benefit energy expenditure via promoting beige adipogenesis [143]. Sclerostin levels have been reported to elevate in car-
diometabolic syndromes [144,145]. Increased sclerostin promotes adipocyte hypertrophy in WAT and fatty liver, leading to an enhancement in inflammatory factor expression and
oxidative stress [9,137]. During CVD, sclerostin in vasculature has been suggested to benefit cardiovascular health by reducing aortic aneurysm, decreasing atherosclerotic plaque
formation, and preventing vascular calcification [13,150,151]. It also plays an anti-inflammation role by attenuating the inflammatory factor expression and aortic macrophage
infiltration [13]. Moreover, sclerostin probably has a direct suppressive effect on monocytes/macrophages by reducing cell adhesion [162,163], inhibiting cell migration [161],
decreasing cholesterol uptake [161], and mitigating inflammatory factor production [159,160], via the inhibition of Wnt/b-catenin pathway in these cells. Short-head arrows:
secretion; differentiation. Long-head arrows: suggested sclerostin effects. Long-head arrows with dash line: hypothesized sclerostin effects. Green texts: direct beneficial effects on
cardiometabolic tissues in T2D or CVD conditions. Blue texts: anti-inflammatory effects in T2D or CVD conditions. Orange texts: direct detrimental effects on cardiometabolic tissues
in T2D or CVD conditions. Red texts: pro-inflammatory effects in T2D or CVD conditions. T2D e type 2 diabetes; CVD e cardiovascular disease; WAT e white adipose tissue.
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in inhibiting vascular calcification requires further investigation. In
addition, as sclerostin probably induces hyperglycemia and hyper-
lipedemia via its actions in adipose tissue, the roles of sclerostin during
CVD development may be multifaceted but remain largely unknown.
Therefore, further investigations are urgently required.
2.13. Complicated role of sclerostin in chronic inflammation
regulation
The association of sclerostin with chronic inflammation has been
suggested because several inflammatory cytokines stimulate sclero-
stin expression in osteocytes under pathological conditions, including
obesity, diabetes, and CVD [156e158]. However, whether sclerostin
modulates chronic inflammation during cardiometabolic diseases re-
mains poorly understood and controversial according to findings of
recent studies. In HFD-fed Sost/ mice, the expression levels of the
inflammatory markers Ccl2, Ccl3, and Ccl4 and the oxidative stress
genes Nox4, Sod1, and Sod2 were decreased in WAT and liver when
compared with WT controls. This finding was consistent with reduced
adiposity in these mice [9]. By contrast, the global overexpression of
Sost in ApoE/ mice was shown to reduce circulating levels of pro-
inflammatory factors and aortic macrophage infiltration during aortic
aneurysm and atherosclerosis, induced by angiotensin II infusion [13].
Understanding the direct effects of sclerostin on monocytes/macro-
phages would greatly enhance the characterization of its role in chronic
inflammation. Despite the insufficient evidence on the direct effects of
sclerostin in myeloid cells, many studies have demonstrated a sup-
pressive effect of sclerostin on monocytes/macrophages inflammation
and migratory capacity via the Wnt/b-catenin signaling pathway
[159e163]. In support of this notion, in both Thp-1 and human primary
monocytes, the activation of the Wnt/b-catenin pathway by lithium or
Wnt3a increases monocyte adhesion to endothelial cells [162,163]. In
human macrophages, Wnt signaling reduction via LRP-5 deficiency
resulted in decreased cholesterol uptake and cell migration [161].
Furthermore, lipopolysaccharides (LPS)-induced b-catenin accumu-
lation has been demonstrated to be involved in cell migration in
RAW264.7 macrophages, and inhibition of the Wnt/b-catenin pathway
via a small-molecule inhibitor attenuated the expression of inflam-
matory factors [159,160].
In summary, the evidence points toward an inhibitory effect of scle-
rostin on monocyte/macrophage inflammation via the Wnt/b-catenin
pathway. Because sclerostin promotes adipositydin turndinitiates
inflammatory responses, the role of sclerostin in chronic inflammation
is probably complicated and may vary by pathological condition
(Figure 3). Therefore, further research, particularly on the direct effects
of sclerostin on inflammatory pathways in adipocytes and monocytes/
macrophages, is required before decisive conclusions can be reached
regarding its role in chronic inflammation.
3. CONCLUSIONS AND PERSPECTIVES
The endocrine action of bone-derived hormones is an emerging,
topical branch of endocrinology and pathophysiology research. In
physiological states, ucOC, LCN2, and sclerostin exert hormonal reg-
ulations in energy metabolism and cardiovascular health. More
importantly, accumulating evidence suggests that the perturbance in
the production and modification of these hormones is closely linked to
the development of T2D and CVD, via regulating several causal factors,
which probably includes chronic inflammation. However, the findings
that suggest the roles of bone-derived hormones in chronic
inflammation are scarce compared with the findings of other well
experimentally supported areas in bone endocrinology. Thus, a
considerable amount of further evidence to support this hormonal
function of bone remains urgently needed from animal and human
studies.
Overall, evidence from the literature supports an anti-inflammatory role
of ucOC in combating T2D and CVD, aligned with its beneficial
metabolic and cardiovascular effects, possibly via the suppression of
ER stress and oxidative stress. By contrast, enhanced circulating levels
and a deamidated form of LCN2 in pathological states appear to
deteriorate CVD conditions, partly via inflammation exacerbation,
although physiologically, it benefits energy metabolism mainly via
anorexigenic effects and enhancing thermogenesis in BAT. As to
sclerostin, the enhancement of sclerostin levels probably perturbs
glucose and lipid homeostasis by promoting adiposity during the
development of T2D. However, sclerostin expressed in cardiovascular
tissues may play a role in inhibiting atherosclerosis progression by
reducing vascular calcification. The role of sclerostin in chronic
inflammation remains complicated, promoting inflammatory reactions
in WAT via enhancing adiposity despite an implicative anti-
inflammation role in vasculature and monocytes/macrophages.
Based on this accumulated knowledge, ucOC administration seems to
have the most therapeutic potential for the management of T2D, CVD,
and chronic inflammation, and the antagonization of LCN2 and scle-
rostin during cardiometabolic disease may also yield beneficial effects.
However, the following questions must be answered in further
mechanistic and pre-clinical research: (1) Compared with non-bone-
produced proteins, especially LCN2, do bone-derived factors play
major roles in pathological conditions? (2) Do these factors exert direct
effects on monocytes/macrophages, especially ucOC and sclerostin?
(3) Will combination treatment involving the modulation of circulating
levels of several bone-derived hormones result in improved therapeutic
outcomes in treating T2D, CVD, and chronic inflammation? Finding
answers to these questions will help elucidate the complex mecha-
nisms underlying the crosstalk between the bone and metabolic and
cardiovascular tissues. In the context of drug discovery, a compre-
hensive understanding of these mechanisms would be a substantial
step toward discovering novel treatments, targeting bone-derived
hormonal pathways, in combating cardiometabolic disorders.
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